Published in J Am Coll Cardiol on October 19, 2005
Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation (2008) 3.48
Applications for ROCK kinase inhibition. Curr Opin Cell Biol (2008) 2.28
Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res (2006) 1.84
Myelin-mediated inhibition of oligodendrocyte precursor differentiation can be overcome by pharmacological modulation of Fyn-RhoA and protein kinase C signalling. Brain (2009) 1.49
Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil. J Cardiovasc Pharmacol (2013) 1.24
Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov Today (2010) 1.24
Rho kinase as a therapeutic target in cardiovascular disease. Future Cardiol (2011) 1.18
Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization. Vasc Health Risk Manag (2010) 1.16
Microvascular coronary dysfunction in women: pathophysiology, diagnosis, and management. Curr Probl Cardiol (2011) 1.08
Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma. PLoS One (2008) 1.08
The therapeutic effects of Rho-ROCK inhibitors on CNS disorders. Ther Clin Risk Manag (2008) 1.04
Rho kinase: an important mediator of atherosclerosis and vascular disease. Curr Pharm Des (2009) 1.04
Rho-associated kinase activity, endothelial function, and cardiovascular risk factors. Arterioscler Thromb Vasc Biol (2011) 1.00
Fasudil, a Rho-kinase inhibitor, attenuates bleomycin-induced pulmonary fibrosis in mice. Int J Mol Sci (2012) 0.98
Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway. Am J Physiol Heart Circ Physiol (2011) 0.97
Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. Br J Pharmacol (2013) 0.95
Antiangiogenic properties of fasudil, a potent Rho-Kinase inhibitor. Jpn J Ophthalmol (2008) 0.93
High-dose fasudil preserves postconditioning against myocardial infarction under hyperglycemia in rats: role of mitochondrial KATP channels. Cardiovasc Diabetol (2012) 0.92
Enhanced rho-associated protein kinase activation in patients with systemic lupus erythematosus. Arthritis Rheum (2013) 0.91
Comparative effectiveness of Di'ao Xin Xue Kang capsule and Compound Danshen tablet in patients with symptomatic chronic stable angina. Sci Rep (2014) 0.90
Rho-associated kinase activity is a predictor of cardiovascular outcomes. Hypertension (2013) 0.86
The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis. Pharmacol Rev (2015) 0.85
The role of rho kinase in sex-dependent vascular dysfunction in type 1 diabetes. Exp Diabetes Res (2010) 0.84
Rho GTPases: Anti- or pro-neoplastic targets? Oncogene (2016) 0.84
Rho kinase inhibition in diabetic kidney disease. Br J Clin Pharmacol (2013) 0.84
Small molecules in the treatment of systemic lupus erythematosus. Clin Immunol (2012) 0.83
Rnd3 haploinsufficient mice are predisposed to hemodynamic stress and develop apoptotic cardiomyopathy with heart failure. Cell Death Dis (2014) 0.82
Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon. Arthritis Care Res (Hoboken) (2012) 0.79
Metabolic actions of Rho-kinase in periphery and brain. Trends Endocrinol Metab (2013) 0.79
Utility of ranolazine in chronic stable angina patients. Vasc Health Risk Manag (2008) 0.78
Angina treatments and prevention of cardiac events: an appraisal of the evidence. Eur Heart J Suppl (2015) 0.78
Selective activation of vascular Kv 7.4/Kv 7.5 K(+) channels by fasudil contributes to its vasorelaxant effect. Br J Pharmacol (2016) 0.77
Stable angina pectoris: antianginal therapies and future directions. Nat Rev Cardiol (2011) 0.77
The Function of Rho-Associated Kinases ROCK1 and ROCK2 in the Pathogenesis of Cardiovascular Disease. Front Pharmacol (2015) 0.77
Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study. BMC Health Serv Res (2015) 0.77
Coronary microvascular dysfunction: sex-specific risk, diagnosis, and therapy. Nat Rev Cardiol (2015) 0.77
Endothelial repair in stented arteries is accelerated by inhibition of Rho-associated protein kinase. Cardiovasc Res (2016) 0.75
Economic evaluation of trimetazidine in the management of chronic stable angina in Greece. BMC Health Serv Res (2016) 0.75
Experimental and early investigational drugs for angina pectoris. Expert Opin Investig Drugs (2016) 0.75
RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations. Stroke (2016) 0.75
Opportunities to Target Specific Contractile Abnormalities with Smooth Muscle Protein Kinase Inhibitors. Pharmaceuticals (Basel) (2010) 0.75
Chronic stable angina is associated with lower health-related quality of life: evidence from Chinese patients. PLoS One (2014) 0.75
Rho-associated kinase activity is an independent predictor of cardiovascular events in acute coronary syndrome. Hypertension (2015) 0.75
Selective inhibition of BET bromodomains. Nature (2010) 18.79
Universal definition of myocardial infarction. Circulation (2007) 11.69
Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med (2012) 8.24
Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol (2002) 6.09
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med (2010) 2.98
Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. Am Heart J (2013) 2.79
Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med (2005) 1.99
Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: results of the CABG surgery cohort of the GUARDIAN study. J Thorac Cardiovasc Surg (2003) 1.64
The benefit of cardiac resynchronization therapy and QRS duration: a meta-analysis. J Cardiovasc Electrophysiol (2011) 1.54
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation (2011) 1.52
Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol (2005) 1.49
Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension. Hypertens Res (2011) 1.42
Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial. J Am Coll Cardiol (2003) 1.39
Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens (2002) 1.36
Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens (2007) 1.33
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol (2005) 1.23
Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study. Ann Thorac Surg (2008) 1.21
Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) (2008) 1.21
Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren. Eur J Heart Fail (2011) 1.18
Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. Am Heart J (2007) 1.05
Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich) (2011) 1.04
A randomized study of the efficacy and safety of intravenous acetaminophen compared to oral acetaminophen for the treatment of fever. Acad Emerg Med (2011) 0.99
Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens (2010) 0.98
The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol (2002) 0.97
[Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Executive summary]. Rev Esp Cardiol (2006) 0.96
Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina. Eur Heart J (2003) 0.95
Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol (2003) 0.95
24-hour efficacy and safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy. J Clin Hypertens (Greenwich) (2011) 0.93
Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. Chem Biol (2013) 0.92
Safety of symptom-limited cardiopulmonary exercise testing in patients with chronic heart failure due to severe left ventricular systolic dysfunction. Am Heart J (2009) 0.89
Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment. Antimicrob Agents Chemother (2006) 0.89
Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study. Cardiovasc Diabetol (2012) 0.89
Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction. Hypertens Res (2009) 0.88
The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens (Greenwich) (2007) 0.88
Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials. Am J Cardiol (2006) 0.87
Multicenter evaluation of SonoVue for improved endocardial border delineation. Echocardiography (2002) 0.87
Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Am J Med Sci (2011) 0.87
Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment. Antimicrob Agents Chemother (2007) 0.86
Telmisartan/Hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension. Hypertens Res (2005) 0.86
Evidence for using clopidogrel alone or in addition to aspirin in post coronary artery bypass surgery patients. Am J Cardiol (2009) 0.86
Synthesis and HDAC inhibitory activity of isosteric thiazoline-oxazole largazole analogs. Bioorg Med Chem Lett (2013) 0.85
Why do they do it? A qualitative study of adolescent drinking and driving. Subst Use Misuse (2003) 0.85
Therapy of stable angina pectoris: the uncomplicated patient. Circulation (2005) 0.84
Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension. J Clin Hypertens (Greenwich) (2012) 0.83
Exercise performance, physical activity, and health-related quality of life in participants with stable angina. Angiology (2011) 0.83
Obesity, brain natriuretic peptide levels and mortality in patients hospitalized with heart failure and preserved left ventricular systolic function. Am J Med Sci (2013) 0.83
Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial. J Sex Med (2011) 0.83
Fungal-specific humoral response in eosinophilic mucus chronic rhinosinusitis. Laryngoscope (2005) 0.83
A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers. J Clin Pharmacol (2013) 0.83
The Rho kinase inhibitor azaindole-1 has long-acting vasodilator activity in the pulmonary vascular bed of the intact chest rat. Can J Physiol Pharmacol (2012) 0.82
Automated external defibrillators in health/fitness facilities: supplement to the AHA/ACSM Recommendations for Cardiovascular Screening, Staffing, and Emergency Policies at Health/Fitness Facilities. Circulation (2002) 0.82
Recurrent and refractory angina following revascularization procedures in patients with stable angina pectoris. Coron Artery Dis (2004) 0.82
Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris. Am J Cardiol (2003) 0.82
Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients. J Clin Hypertens (Greenwich) (2008) 0.82
Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction. Clin Pharmacokinet (2002) 0.81
Nasal polyp cell populations and fungal-specific peripheral blood lymphocyte proliferation in allergic fungal sinusitis. Am J Rhinol Allergy (2009) 0.81
Use of hydralazine-isosorbide dinitrate combination in African American and other race/ethnic group patients with heart failure and reduced left ventricular ejection fraction. J Am Heart Assoc (2013) 0.81
Pharmacokinetics, safety profile, and efficacy of aliskiren in pediatric patients with hypertension. Clin Pediatr (Phila) (2013) 0.81
Triple-combination treatment with olmesartan medoxomil/amlodipine/ hydrochlorothiazide in Hispanic/Latino patients with hypertension: the TRINITY study. Ethn Dis (2014) 0.80
Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. Blood Press Monit (2008) 0.80
Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment. J Clin Pharmacol (2007) 0.80
Eosinophilic mucus chronic rhinosinusitis: clinical subgroups or a homogeneous pathogenic entity? Laryngoscope (2006) 0.80
Dihalocarbene insertion reactions into C-H bonds of compounds containing small rings: mechanisms and regio- and stereoselectivities. J Org Chem (2007) 0.80
Nitrates as an integral part of optimal medical therapy and cardiac rehabilitation for stable angina: review of current concepts and therapeutics. Clin Cardiol (2012) 0.80
Proteomic analysis of lupin seed proteins to identify conglutin Beta as an allergen, Lup an 1. J Agric Food Chem (2008) 0.80
Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer (2004) 0.78
Color encoding of endocardial motion improves the interpretation of contrast-enhanced echocardiographic stress tests by less-experienced readers. J Am Soc Echocardiogr (2006) 0.78
Anemia and associated clinical outcomes in patients with heart failure due to reduced left ventricular systolic function. Clin Cardiol (2013) 0.78
Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension. Hypertension (2009) 0.78
Pharmacokinetics and safety of binodenoson after intravenous dose escalation in healthy volunteers. J Nucl Cardiol (2005) 0.78
Blood pressure effects of naproxcinod in hypertensive patients. J Clin Hypertens (Greenwich) (2011) 0.77
Review of the safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Postgrad Med (2011) 0.77
Photorearrangement of alpha-azoxy ketones and triplet sensitization of azoxy compounds. J Org Chem (2005) 0.77
Single-dose effects of isosorbide mononitrate alone or in combination with losartan on central blood pressure. J Am Soc Hypertens (2010) 0.76
Efficacy, safety and pharmacokinetics of a novel subcutaneous immunoglobulin, Evogam®, in primary immunodeficiency. J Clin Immunol (2012) 0.76
An immunodiagnostic assay for quantitation of specific IgE to the major pollen allergen component, Pas n 1, of the subtropical Bahia grass. Int Arch Allergy Immunol (2015) 0.76
Selective L-type, T-type, and nonspecific calcium-channel blockers for stable angina pectoris. Am Heart J (2002) 0.75
The TRINITY Study: distribution of systolic blood pressure reductions. Integr Blood Press Control (2013) 0.75
Intranasal ciclesonide for allergic rhinitis. J Asthma Allergy (2008) 0.75
Effect of telcagepant on spontaneous ischemia in cardiovascular patients in a randomized study. Headache (2011) 0.75
Treatment with statins in high-risk patients: relevance of time to titration of dose and adverse outcomes. Am J Cardiovasc Drugs (2009) 0.75
ACEI associated angioedema. Aust Fam Physician (2012) 0.75
Osteoprotegerin and ST segment myocardial infarction: a novel risk marker but not for routine use at present. Cardiology (2012) 0.75
Prevention of nitrate tolerance with angiotensin II receptor type 1 blocker in patients with stable angina: yet another failed strategy to prevent tolerance. Cardiovasc Drugs Ther (2004) 0.75
The pharmacokinetics of PF-734200, a DPP-IV inhibitor, in subjects with renal insufficiency. Br J Clin Pharmacol (2011) 0.75
Capsaicin not homeopathic. Ann Allergy Asthma Immunol (2011) 0.75